The United States does not do very well in a recent study measuring the health-related sustainable development goals in 188 countries, due to decades of growing obesity and ongoing violence.
Eleven Biotherapeutics announced that it has entered into a definitive agreement to acquire Viventia and its lead product candidates Vicinium and Proxinium.
Tobira Therapeutics shares skyrocketed on Tuesday after Allergan announced that it will acquire the company.
Shares of Puma Biotechnology had a strong gain in Tuesday’s session following some positive news from the FDA on the company's breast cancer treatment.
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Shares of Community Health Systems retreated on Monday, after making a sizable gain in Friday’s session on news that the company might be pursuing an option to sell.
An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four top biotech companies may be a solid play now.
Novavax was pummeled by shareholders on Friday after the company reported top-line results from its RSV F Vaccine trials.
Shares of AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) surged following positive results from a late-stage trial. The company announced the outcome of an open-label Phase 3 trial (SAP303) of investigational product candidate ARX-04. Let us just say, it…
Caladrius Biosciences watched its shares soar on Thursday after the company announced a private placement offering.
Shares of Aeri Pharmaceuticals skyrocketed early Thursday after the company issued positive results on its intraocular pressure (IOP) treatment in patients with glaucoma.
Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy.
It is not that often that you see biotech or biohealth stocks moving north of 50% in one trading session. If you do it is usually due to merger news or a rumor about…
Agios Pharmaceuticals has filed with the SEC regarding a secondary offering of up to $150 million of its common stock.
The goal of Allergan’s bid for Vitae Pharmaceuticals is to bolster its dermatology product pipeline, and Vitae shareholders appear happy to oblige.
